

PRESS RELEASE
20 March 2023 08:30:00 CET

Stockholm3 study awarded as one of the best abstracts of the 2023 annual European Association of Urology meeting

The 38th annual European Association of Urology (EAU) meeting was held March 10-13, 2023 in Milan, Italy. More sophisticated risk adapted strategies was a focus area, including seven abstracts evaluating Stockholm3 performance in populations across Europe. For the third year in a row a Stockholm3 study was awarded and highlighted on the plenary session.

The awarded Stockholm3 presentation was based on preliminary mortality results for the 245,905 men that were eligible for the STHLM3 clinical trial carried out at the Karolinska institute in Stockholm 2012 to 2014. Of the eligible men, 68 percent were invited to participate and take a one-time Stockholm3 test and of these, 35 percent participated. The interim analysis showed after 6.5 years of follow-up that the prostate cancer-specific mortality was trending towards lower mortality in the invited group compared to the non-invited group, which was heavily PSA tested, with a risk ratio of 0.76 (98 percent CI: 0.50-1.14).

The abstract won second prize in the Best Abstract Awards Oncology category, and the results were discussed at a session on the final day of the conference where the chair of the EAU Scientific Congress Office, Prof. Peter Albers, aimed to highlight the “highest quality and most impactful” abstracts selected for prize. This was the third year in a row a Stockholm3 study was awarded and highlighted on the plenary stage.

“An advantage with the trials conducted in Sweden is the linkage of the participants to high quality national register data. Evaluation of both long-term mortality differences from Stockholm3-based screening and evaluation of 2-year follow-up intervals as nested in the design of the STHLM3-MRI trial will be important to report to the community in future follow-up,” says Dr. Hari Vigneswaran, Director of Medical Affairs at A3P Biomedical.

Other Stockholm3 presentations covered a wide range of topics including independent validations in different German and Swiss cohorts, Stockholm3 as a risk stratification tool with MRI, and head-to-head comparisons with other risk stratification tools. The full list of abstracts is available below.

“EAU was a big success for us. We are proud that we are in the scientific forefront in our field. This meeting was a clear indicator that the interest is now starting to pick up to start using the test broadly and I expect that more well renowned clinics will start using Stockholm3 in the near future in Europe and beyond,” says David Rosén CEO of A3P Biomedical.

List of Stockholm3 publications presented at EAU

Abstract title	Presenting author, city	Session	Date /location
Prostate biopsies can be omitted in most patients with a positive Stockholm3-test and a negative prostate magnetic resonance imaging	M.N. Vigmostad, Stavanger (NO)	Abstract session 04	Friday March 10th, 15:15-16:45
External validation of Stockholm3 in a retrospective German clinical cohort	D. Tilki, Hamburg (DE)	Abstract session 04	Friday March 10th, 15:15-16:45
The Capio S:t Görän model for prostate cancer diagnosis using Stockholm3, magnetic resonance imaging and targeted biopsies	T. Palsdottir, Solna (SE)	Abstract session 04	Friday March 10th, 15:15-16:45
Update on current screening trials - STHLM3	T. Nordström, Stockholm (SE)	Plenary session, Yellow area, eURO Auditorium 1	Sunday March 12th, 8:00-10:30
Experiences from the Swedish population based organised prostate cancer testing programme	O. Bratt, Gothenburg (SE)	Thematic session, Yellow area, eURO Auditorium 1	Sunday March 12th, 13:45-15:15
The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up	C. Micoli, Stockholm (SE)	Abstract session 48	Sunday March 12th, 17:30-19:00
Repeat prostate cancer screening using prostate-specific antigen, a multiplex blood-test and magnetic resonance imaging: 2nd screening round outcomes of STHLM3-MRI	T. Nordström, Stockholm (SE)	Abstract session 48	Sunday March 12th, 17:30-19:00
Prospective multicenter validation of the Stockholm-3 (STHLM3) test in a Middle European population	A. Elyan, Basel (CH)	Abstract session 48	Sunday March 12th, 17:30-19:00
External validation of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and comparison to Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort	T. Palsdottir, Solna (SE)	Abstract session 48	Sunday March 12th, 17:30-19:00

For additional information, please contact:

David Rosen, CEO
 Telephone: +46 10 1823325
 Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

(1) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

[Stockholm3 study awarded as one of the best abstracts of the 2023 annual European Association of Urology meeting](#)